Thursday, September 17

Browsing: misses

General

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

By Healthcare Propulsion StaffSeptember 15, 20260

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as…

What's Hot

Austin group urges support for mental health, jobs over police surveillance

Scalable machine learning model maps complex genomic enhancers across tissues

Blue Shield of California to expand Virtual Blue program

Browsing: misses

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

GLP-1 drugs could reshape fashion and body culture

Oral drug offers promising advance for children with achondroplasia

Prednisone may impair bone health in children with Duchenne muscular dystrophy

Inside Epic’s Push to Help Customers Build Their Own AI Agents Using Agent Factory

Austin group urges support for mental health, jobs over police surveillance

Scalable machine learning model maps complex genomic enhancers across tissues

Blue Shield of California to expand Virtual Blue program

Can AI find drugs to fight infection?

Our Picks

Austin group urges support for mental health, jobs over police surveillance

Scalable machine learning model maps complex genomic enhancers across tissues

Subscribe to Updates

What's Hot

Browsing: misses

Subscribe to Updates